ReNeuron Group plc

Management did not give a full income statement on the call, but said revenue was “up slightly,” the cost base “reduced quite significantly” versus the prior year, and that this led to a lower loss for the year. Cash at 31 March was $7.2 million, which management said was ahead of market expectations, and runway extends into 2024. The 40% reduction in headcount was cited as part of the restructure, and management said the current cash would take the company into quarter 2024, with the forecast assuming some extra funding extending runway into the middle of 2024. No EPS or gross margin figures were stated. Forward-looking commentary centered on in vivo data expected in 2 to 3 months, with management hoping that data will support collaborations, licensing discussions, and possibly non-dilutive funding.

Executive Chairman Iain Ross framed the quarter as execution against the plan set at the start of the year: develop the drug delivery platform, generate data, and use that data to drive partnerships. His tone was confident and defensive of the strategy, repeatedly stressing that the company is focused, transparent, and spending shareholder money carefully. He also said the business is now in a better position than before because people are coming to them, rather than the company having to pitch the platform aggressively.

John Hawkins said January restructuring realigned resources toward validating CustomEX, with a 40% headcount reduction and lower variable costs. He emphasized cash preservation, saying cash at 31 March was $7.2 million and runway extends into 2024; he also noted that the cash position was ahead of market expectation. He added that, without further funding, cash would take the company into quarter 2024, while the forecast assumes some additional funding and extends runway into the middle of 2024. He did not discuss gross margin or EPS.

Questions focused on when data would be available, whether partnerships or deals could follow quickly, and whether the company might need more cash. Management said the key in vivo studies are running in parallel and will feed out in the next 2 to 3 months, but cautioned that big pharma can take time even after good data is delivered. They also said financing remains difficult, so the preferred route is non-dilutive partnering, though they would approach shareholders if they had a compelling case. On Codiak, management said that company’s failure showed the risk of betting on therapeutics, and ReNeuron has no intention of pursuing that model.